MedAxiom has been acquired by American College of Cardiology
March 2019 — The private shareholders of MedAxiom have sold the company to American College of Cardiology, Inc.
MedAxiom was founded in 2001 and is the nation’s leading cardiovascular performance community serving physician practices by providing expert consulting, networking and membership services including data analytics, program excellence tools and educational events to improve business and patient care outcomes.
American College of Cardiology is a trade association that caters to cardiovascular professionals to learn, grow and share knowledge about cardiovascular care and heart health. It also reviews and offers certification courses focusing on cardiovascular diseases. The association helps in the formation of cardiology guidelines, clinical data standards and health policies. Additionally, it publishes cardiovascular journals which focus on cardiovascular diseases, including original clinical studies, translational investigations with clear clinical relevance, state-of-the-art papers, review articles, and editorials interpreting and commenting on the research presented. American College of Cardiology was founded in 1949 and is based in Washington, DC.
Our role in the transaction
Oaklins’ teams in Jacksonville and Savannah acted as financial advisors to MedAxiom in this transaction.
Jennifer Linville
Founding CEO, MedAxiom
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreSynergia and Bolster have secured acquisition financing for Life & Mobility
Synergia Capital Partners and Bolster Investment Partners have partnered with Life & Mobility, a leading Dutch developer and manufacturer of premium mobility and rehabilitation solutions. The partnership marks an important next step in Life & Mobility’s growth trajectory, focused on further international expansion, continued product innovation and strengthening its leading market position.
Learn more